Natural killer cell immunotherapy in glioblastoma
Abstract Glioblastoma (GBM) is one of the most difficult cancers to treat because GBM has the high therapeutic resistance. Recently, immunotherapies for GBM have been used instead of conventional treatments. Among them, Natural killer (NK) cell-based immunotherapy has the potential to treat GBM due...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2022-10-01
|
| Series: | Discover Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s12672-022-00567-1 |
| _version_ | 1811192375847944192 |
|---|---|
| author | Hamed Hosseinalizadeh Mehryar Habibi Roudkenar Amaneh Mohammadi Roushandeh Yoshikazu Kuwahara Kazuo Tomita Tomoaki Sato |
| author_facet | Hamed Hosseinalizadeh Mehryar Habibi Roudkenar Amaneh Mohammadi Roushandeh Yoshikazu Kuwahara Kazuo Tomita Tomoaki Sato |
| author_sort | Hamed Hosseinalizadeh |
| collection | DOAJ |
| description | Abstract Glioblastoma (GBM) is one of the most difficult cancers to treat because GBM has the high therapeutic resistance. Recently, immunotherapies for GBM have been used instead of conventional treatments. Among them, Natural killer (NK) cell-based immunotherapy has the potential to treat GBM due to its properties such as the absence of restriction by antigen-antibody reaction and deep penetration into the tumor microenvironment. Especially, genetically engineered NK cells, such as chimeric antigen receptor (CAR)-NK cells, dual antigen-targeting CAR NK cells, and adapter chimeric antigen receptor NK cells are considered to be an important tool for GBM immunotherapy. Therefore, this review describes the recent efforts of NK cell-based immunotherapy in GBM patients. We also describe key receptors expressing on NK cells such as killer cell immunoglobulin-like receptor, CD16, and natural killer group 2, member D (NKG2DL) receptor and discuss the function and importance of these molecules. |
| first_indexed | 2024-04-11T23:51:41Z |
| format | Article |
| id | doaj.art-3618d8d576554817893157a27b68a611 |
| institution | Directory Open Access Journal |
| issn | 2730-6011 |
| language | English |
| last_indexed | 2024-04-11T23:51:41Z |
| publishDate | 2022-10-01 |
| publisher | Springer |
| record_format | Article |
| series | Discover Oncology |
| spelling | doaj.art-3618d8d576554817893157a27b68a6112022-12-22T03:56:28ZengSpringerDiscover Oncology2730-60112022-10-0113111910.1007/s12672-022-00567-1Natural killer cell immunotherapy in glioblastomaHamed Hosseinalizadeh0Mehryar Habibi Roudkenar1Amaneh Mohammadi Roushandeh2Yoshikazu Kuwahara3Kazuo Tomita4Tomoaki Sato5Department of Medical Biotechnology, Faculty of Paramedicine, Guilan University of Medical SciencesBurn and Regenerative Medicine Research Center, School of Medicine, Velayat Hospital, Guilan University of Medical SciencesBurn and Regenerative Medicine Research Center, School of Medicine, Velayat Hospital, Guilan University of Medical SciencesDivision of Radiation Biology and Medicine, Faculty of Medicine, Tohoku Medical and Pharmaceutical UniversityDepartment of Applied Pharmacology, Graduate School of Medical and Dental Sciences, Kagoshima UniversityDepartment of Applied Pharmacology, Graduate School of Medical and Dental Sciences, Kagoshima UniversityAbstract Glioblastoma (GBM) is one of the most difficult cancers to treat because GBM has the high therapeutic resistance. Recently, immunotherapies for GBM have been used instead of conventional treatments. Among them, Natural killer (NK) cell-based immunotherapy has the potential to treat GBM due to its properties such as the absence of restriction by antigen-antibody reaction and deep penetration into the tumor microenvironment. Especially, genetically engineered NK cells, such as chimeric antigen receptor (CAR)-NK cells, dual antigen-targeting CAR NK cells, and adapter chimeric antigen receptor NK cells are considered to be an important tool for GBM immunotherapy. Therefore, this review describes the recent efforts of NK cell-based immunotherapy in GBM patients. We also describe key receptors expressing on NK cells such as killer cell immunoglobulin-like receptor, CD16, and natural killer group 2, member D (NKG2DL) receptor and discuss the function and importance of these molecules.https://doi.org/10.1007/s12672-022-00567-1GlioblastomaNK cellsImmunotherapy |
| spellingShingle | Hamed Hosseinalizadeh Mehryar Habibi Roudkenar Amaneh Mohammadi Roushandeh Yoshikazu Kuwahara Kazuo Tomita Tomoaki Sato Natural killer cell immunotherapy in glioblastoma Discover Oncology Glioblastoma NK cells Immunotherapy |
| title | Natural killer cell immunotherapy in glioblastoma |
| title_full | Natural killer cell immunotherapy in glioblastoma |
| title_fullStr | Natural killer cell immunotherapy in glioblastoma |
| title_full_unstemmed | Natural killer cell immunotherapy in glioblastoma |
| title_short | Natural killer cell immunotherapy in glioblastoma |
| title_sort | natural killer cell immunotherapy in glioblastoma |
| topic | Glioblastoma NK cells Immunotherapy |
| url | https://doi.org/10.1007/s12672-022-00567-1 |
| work_keys_str_mv | AT hamedhosseinalizadeh naturalkillercellimmunotherapyinglioblastoma AT mehryarhabibiroudkenar naturalkillercellimmunotherapyinglioblastoma AT amanehmohammadiroushandeh naturalkillercellimmunotherapyinglioblastoma AT yoshikazukuwahara naturalkillercellimmunotherapyinglioblastoma AT kazuotomita naturalkillercellimmunotherapyinglioblastoma AT tomoakisato naturalkillercellimmunotherapyinglioblastoma |